RSS Feed
December 24th, 2015 
Awake Goy 
Susanne Posel ,Chief Editor Occupy Corporatism | Co-Founder, Legacy Bio-Naturals
December 24, 2015
GW Pharmaceuticals stock trading has gone green thanks to an announcement that Epidiolex data was highly positive.
This is thanks to a study published by the Comprehensive Epilepsy Center at NYU Langone Medical Center that shows Cannibidiol (CBD) can reduce seizures in children and adults that suffer from epilepsy.
The researchers combined data from 137 patients between the ages of 1 and 30 year of age from 11 epilepsy centers in the US. CBD reduced seizure frequency in most of the children and adults studied.
As an “open-label” trial, the participants knew they were being given CBD over 12 weeks via GW Pharma’s synthetic product called Epidiolex .
Caregivers logged seizures in “diaries” which were reviewed by researchers. It was determined that 36.5% of motor seizures were reduced per month.
Simultaneously, the Drug Enforcement Administration (DEA) announced they will relax restrictions on CBD research for medicinal use.
Essentially the DEA has rolled back the requirements imposed by the Controlled Substances Act (CSA) which directly effects studies on CBD.
Per the DEA changes “a previously registered CBD clinical researcher who is granted a waiver can readily modify the protocol and continue research” without a hitch.
Related Posts
Source Article from http://feedproxy.google.com/~r/OccupyCorporatism/~3/EdoQ2bqGbqo/
Posted in 
Tags: 
